The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.
|Recipient||Amount||Start Date||End Date|
|Dana-farber Cancer Institute, Inc.||$ 2,533,281||   ||1989-07-01||2019-07-31|
|Cleveland Clinic Lerner College Of Medicine/cwru||$ 420,976||   ||2014-08-15||2019-07-31|
|Trustees Of Princeton University, The||$ 2,427,500||   ||2013-09-30||2018-08-31|
|Trustees Of Boston University||$ 710,161||   ||2010-06-08||2016-05-31|
|Hemosonics, Llc||$ 202,931||   ||2014-07-09||2016-03-31|
|Novab, Inc.||$ 149,036||   ||2014-09-25||2016-03-24|
|University Of California, Davis||$ 1,673,148||   ||2010-04-01||2016-01-31|
|Virginia Commonwealth University||$ 1,599,061||   ||2010-04-01||2016-01-31|
|Trustees Of The University Of Pennsylvania, The||$ 1,573,613||   ||2010-04-01||2016-01-31|
|Weill Medical College Of Cornell University||$ 2,555,009||   ||2010-02-01||2015-12-31|
Fiscal Year 2016: In FY2016, 340 competing RPG awards were made, which were 11.3% of the applications received. In FY2016, 10 competing SBIT/STTR awards were made, which were 7.4% of the applications received. Fiscal Year 2017: In FY2017, the estimated total awards to be made are 1308. Fiscal Year 2018: In FY2018, the estimated total awards to be made are 1095.
Uses and Use Restrictions
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects.
The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and Facilities and Administrative Costs (formerly known as indirect costs).
The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant for support of research by a named principal investigator.
To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.
For-profit organizations' costs are determined in accordance with Subpart 31.2 of the Federal Acquisition Regulations. For other grantees, costs will be determined in accordance with HHS Regulations 45 CFR Part 75 See the website for more information on the electronic submission of grants. 2 CFR 200, Subpart E - Cost Principles applies to this program.
Aplication and Award Process
Preapplication coordination is not applicable.
Environmental impact information is not required for this program.
This program is excluded from coverage under E.O.
2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. The NIH is in the process of a transition to fully electronic grant submission through Grants.gov (see http://era.nih.gov/ElectronicReceipt for details). Depending on the grant mechanism, either form PHS-398 (Rev. June 2009) or form SF424(R&R) (January 2010) is the standard form. Both can be obtained at http://grants1.nih.gov/grants/forms.htm. The standard application forms, as furnished by PHS must be used for this program. The following is a website address for NIH electronic submission of grant application information: http://era.nih.gov/ElectronicReceipt/index.htm.
Grants and cooperative agreements are funded based on scientific merit, program relevance, and program balance and are made annually. The initial grant award provides funds for the first budget period (usually 12 months) and letter Notice of Award indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories and special conditions, if any.
Aug 05, 2018 All Grants including renewals and supplements: April 5, August 5, December 5. Cooperative Agreements and contracts are usually submitted in response to a Request for Applications (RFA) or a Request for Proposals (RFP). The receipt date is stipulated in the RFA or RFP. Note that for New Investigator and Early Stage Investigators applying for an R01 resubmission there are expedited review dates described in NOT-OD-11-057 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-057.html).
Public Health Service Act, Section 301, 410, and 411, Public Law 78-410, 42 U.S.C. 241, as amended; Public Law 100-607, 42 U.S.C. 285 and 285a; Small Business Research and Development Enhancement, Act of 1992, as amended, Public Law 102-564.
Range of Approval/Disapproval Time
Regular Grants: Approximately 10 months.
A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page www.nih.gov/grants/guide/notice-files/not97-232.html.
Applications submitted for renewal are reviewed and selected for funding on a competitive basis.
Formula and Matching Requirements
This program has no statutory formula. This program has no matching requirements. This program does not have MOE requirements.
Length and Time Phasing of Assistance
Grants and Cooperative Agreements: Average 3 to 5 years, and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or an Electronic Transfer System. Method of awarding/releasing assistance: by letter of credit.
Post Assistance Requirements
No program reports are required.
No cash reports are required.
Progress reports are required each year.
Annual financial status report is required 90 days after the end of the budget period.
Special reports may be requested by DHHS.
Terminal reports are required 6 months after the end of a project.
Expenditure reports are not applicable.
Performance monitoring is not applicable.
In accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, non-Federal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 2 CFR 200.503. In addition, grants and cooperative agreements are subject to inspection and audits by DHHS and other Federal government officials.
Expenditures and other financial records must be retained for 3 years from the day on which the grantee submits the last financial status report for the report period.
75-0849-0-1-550 - Cancer Biology Research.
(Salaries) FY 16 $523,277,000; FY 17 est $569,576,000; and FY 18 est $475,693,000 - Cancer Biology Research Grants FY2016 act. $510,555,000- SBIR/STTR $3,905,000 - Other Research $8,839,000 FY2017 est. $539,414,000 - SBIR/STTR $4,260,000 - Other Research $25,902,000 FY2018 est. $451,368,000 - SBIR/STTR $3,291,000 - Other Research $21,034,000.
Range and Average of Financial Assistance
Range: $15,589 to $4,445,418 Average: $387,077.
Regulations, Guidelines, and Literature
42 CFR 52; 45 CFR 75; Grants will be available under the authority of and administered in accordance with the PHS Grants Policy Statement and Federal regulations at 42 CFR 52 and 42 U.S.C. 241; Omnibus Solicitation of the Public Health Service for Small Business Innovation Research (SBIR) Grant and Cooperative Agreement Applications. Omnibus Solicitation of the National Institutes of Health for Small Business Technology Transfer (STTR) Grant Applications.
Regional or Local Office
Shamala K. Srinivas 9609 Medical Center Drive Seventh Floor, West Tower, 7W530, MSC 9750, Rockville, Maryland 20850 Email: firstname.lastname@example.org Phone: 240-276-6442 Fax: 240-276-7682
Criteria for Selecting Proposals
The government-backed Social Investment Research Council is newly formed to hatch practical insights into social investment market products, and the investors needed to finance them.